Medicare’s spending on ‘ultra-expensive’ drugs increased by 1,170% in 6 years

As more drugs enter the market with five-figure annual list prices, a large share of Medicare’s drug spending is going toward these “ultra-expensive” treatments, according to research published June 7 in Health Affairs.

Advertisement

The study found that Medicare Part D’s share of annual spending on ultra-expensive drugs increased by 1,170 percent between 2012 and 2018, largely because more beneficiaries were prescribed such drugs during this time period.

The researchers said their findings underscore a national conversation about ultra-expensive drug’s sustainability and affordability. 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Download Whitepaper

The cost-saving opportunity most health systems overlook

Many hospitals and health systems scrutinize staffing, service lines, and payer contracts for savings. Fewer look at one of their largest assets: real estate.…

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.